Background: Different doses of phytosterols/-stanols up to a maximum of 4.0 g/day have been used in human safety studies, whereas only one small-scale study investigated some detailed clinical information about consumption levels exceeding 8.6 g/ day.
Introduction
It is well known that phytosterols and phytostanols interfere with the uptake of both dietary and biliary cholesterol from the intestinal tract. Several studies have shown that foods enriched with phytosterols or phytostanols reduce total blood cholesterol levels by an average of 5-15% and LDLcholesterol levels by an average of 10-20% (Nguyen, 1999; Law, 2000) . A daily intake of 1.5-3.0 g of phytosterols or phytostanols is considered to be the optimal amount for lowering cholesterol levels, because no additional benefit is derived from an intake above this range, which could be concluded from results of clinical trials (among others: Hendriks et al, 1999) , or from interpreting the literature (Miettinen et al, 1995; Hendriks et al, 1999; Maki et al, 2001) . Up till now, few adverse effects related to either short-term or longer-term consumption of the phytosterols or phytostanols have been reported. Many studies show a small, but significant decrease (about 25%) in serum b-carotene levels and a 5-15% lowering effect on several other blood carotenoids after consumption of plant sterols or stanols Hendriks et al, 1999; Mensink et al, 2002; Scientific Committee on Food 2002b) . Subjects, participating in these studies, still had b-carotene concentrations within the normal range and the reduction still falls within the seasonal variation. This is explained by the wide range of the individual baseline or control values for blood b-carotene among the participants in the trials. The question remains, however, whether the 25% reduction is acceptable for the individual as subjects with higher levels may have a lower risk for cancer and/or cardiovascular diseases. Also, a tendency is apparent from the literature that the longer the duration of phytosterol consumption, the larger the decrease in blood carotenoid concentration. The reduction in blood b-carotene might also be of importance in subjects with a suboptimal vitamin A status. Also, some other potential benefits of carotenoids not directly related to vitamin A formation can become compromised, for example, antioxidant and anticarcinogenic activities as well as regulators of several cellular functions. No definite conclusions can be drawn with respect to these adverse effects, but further research is certainly advocated (Scientific Committee on Food, 2002a) . According to results of short-term studies, concentrations of other fat-soluble vitamins remain largely unaffected (Plat & Mensink, 2001b) , although effects on vitamin K concentrations are not clear (Plat & Mensink, 2000) .
In some reports, it has been suggested that unsaturated phytosterols may have an impact on oestrogenic activity (see Ayesh et al (1999) for an overview), but there may have been flaws in the design of these studies. In their own studies, Ayesh et al (1999) investigated the effect of phytosterols on gut microflora, faecal short-chain fatty acids and serum female sex hormones. There was a statistically significant reduction in serum progesterone levels in the female subjects after the intervention, but according to the authors the biological significance of these results were considered to be of no major importance. No effects of the phytosterol-enriched margarines were found on the bacterial profile or the metabolic activities of the gut microflora. Also, animal studies on reproductive toxicology aspects suggested no serious effects (see for references, Raulio et al, 2001 ; Scientific Committee on Food 2002a). Whether consumption of phytosterols is positively or negatively related to certain types of cancer has not been established yet (Jones & Raeini-Sarjaz, 2001; Normen et al. 2001) .
Although the phytosterols and phytostanols are poorly absorbed, a continuous load causes an increase in plasma concentrations. The proportion that is absorbed depends on the chemical structure, varying from 1-2% for sitostanol and campestanol to 13% for campesterol. The increase in plasma concentrations may especially be a problem in people with a family history of coronary heart diseases (Sudhop et al. 2002) and people with sitosterolaemia (Bhattacharyya et al, 1991; Salen et al, 1992) as these higher plasma concentrations can lead to severe and premature atherosclerosis (Scientific Committee on Food, 2002a) . The phytosterol absorption may be enhanced by the simultaneous use of cholesterollowering drugs such as statins Gylling & Miettinen, 2002) . Small amounts may get incorporated in various tissues such as liver, aorta, lungs and red blood cells. Whether this leads to any metabolic effects in humans also remains to be investigated (Plat & Mensink, 2001a) . The difference in absorption between phytosterols and phytostanols has certainly induced a debate about whether to approve and use phytostanols only for the enrichment of food products.
Different doses of phytosterols or phytostanols have been used in several safety studies. To our knowledge, the largest dose used to measure treatment effects has been 4.0 g/day (Plat, 2001) . Ayesh et al (1999) have used a dose of 8.6 g/day for 21 and 28 days, respectively, in their studies focusing on clinical outcomes other than the specific treatment effects. More than two decades ago, Lees et al (1977) performed two studies in which a total of 18 hyperlipidaemic patients received an average dose of 18 g of a mixture of campesterol and sitosterol per day for 307 and 310 days, respectively. No adverse effects were observed in this latter study although the data indicated that significant quantities of campesterol were absorbed. Unfortunately, no other biomedical markers were measured in that study. As a consequence, detailed clinical information about consumption levels exceeding 8.6 g/day in humans is lacking.
Margarines enriched with phytostanols were first launched on the Finnish market in 1995. In addition to these margarines, several other stanol-enriched foods (fresh cheese, yoghurt, snack bars, salad dressing) have followed in Finland as well as in some other countries. Phytosterolenriched margarines entered among others the Australian and US market in 1999 and the rest of the EU market in 2000. Manufacturers have applied to market other phytosterol-enriched foods too, following the phytostanol examples. Consumers might use several products simultaneously and might receive higher doses than anticipated. As we do not know the effects of the relatively high doses (eg 8.6 g/ day) of phytosterols or phytostanols in the long term, we should make an effort to quantify this problem and to investigate whether alertness is warranted taking the abovedescribed safety issues into account. The objective of our simulation study was, therefore, to determine the distribution of intake in the general population as well as the intake in groups likely to be at risk of excessive intakes if liberal fortification of foods enriched with phytosterols and phytostanols proceeds.
Subjects and methods
The data for the study were obtained from the 'Monitoring Project on Risk Factors for Chronic Diseases' (MORGENproject), conducted by the National Institute for Public Health and the Environment (RIVM) in Bilthoven, the Netherlands. Its general purpose was to determine the prevalence of risk factors for chronic diseases in a representative sample of the general Dutch population. The sample used in our data-analyses, consisted of 23 106 persons aged 20-60 years in three Dutch towns (Amsterdam, Doetinchem, Maastricht). Data were collected from 1993 to 1997. The MORGEN study was approved according to the guidelines of the Helsinki Declaration by the external Medical Ethical Committee of the Dutch TNO Research Institute.
Data collection in the MORGEN-project was based on two self-administered questionnaires and a medical examination. The first questionnaire contained questions on demographic characteristics, presence of chronic diseases, risk factors for chronic diseases, self-rated health and psycho-social conditions. Second, a food frequency questionnaire (FFQ) consisting of 178 food and supplement intake items was distributed. The FFQ and its validity have been described in more detail by Ocké et al (1997a, b) . A medical examination was performed at the Municipal Health Service in each town, according to standardised protocols. It consisted of measurements of blood pressure, anthropometric measurements (height, weight, waist-hip circumference), blood sampling and spirometry. Details of this study have been described elsewhere (Houterman et al, 2001) . General characteristics of the study population as has been used in the current study (n¼22 714) are presented in Table 1 .
Simulation procedure
The intake and distribution of plant sterols was assessed by virtually replacing one to four ordinary foods in the diet by candidate products enriched with sterols or stanols. Foods were selected for the study based on decisions already taken with regard to market admittance and current applications for admittance (Gezondheidsraad: Commissie Veiligheidsbeoordeling van nieuwe voedingsmiddelen, 2001 ). The doses recommended by the producers have been used in the simulation procedures. The aim was to choose pragmatically the most likely combinations of foods for different segments of the Dutch population as this population is a dairy and bread-eating population that uses mainly cheese and cold cuts as sandwich fillings (Table 2) .
Calculations were made for groups of people stratified by gender and within the strata further divided into groups differing in age, social economic status (SES), body mass index (BMI), total plasma cholesterol levels, alcohol consumption, smoking habits, subjective health, presence of self-reported cardiovascular diseases, high blood pressure, diabetes, and for women: a current pregnancy. SES was categorised into three classes: low (intermediate secondary education or less), middle (intermediate vocational or higher secondary education) or high (higher vocational or university education).
In agreement with other simulation studies (Brussaard et al, 1995; Firth et al, 1998; Raulio et al, 2001; Suojanen et al, 2002 ) the simulated intake of phytosterols/-stanols was calculated as follows:
Simulated intake sterols/stanols¼intake of the particular food (g/day) * Phytosterol/-stanol content in the particular food.
In case several foods were simultaneously replaced in the simulation procedures, the sum over the different foods was Simulated intake of phytosterols/-stanols N De Jong et al calculated. We did not take into account the amount of phytosterols/-stanols naturally occurring in the diet because this amount is negligible compared to the concentration in the enriched products (eg in the Dutch diet the mean7s.d. total sterol intake approximates 285797 mg/day (Normen et al, 2001) , which is in line with earlier figures presented for the general Western diet: for example, 100-300 mg phytosterols and 20-50 mg phytostanols daily (Nguyen, 1999) . For the calculations we assumed that the nonenriched foods were entirely replaced by the enriched foods. Percentiles (P25, P50, P75, P90) have been used to present the distribution in intake for different segments of the study group. Analysis of variance (ANOVA) was used to estimate the differences in phytosterol/-stanol intake among the different subgroups within the strata followed by a post hoc comparison (Tukey). We used a backward multiple linear regression analysis to describe the contribution of the variables to the final estimated phytosterol/-stanol intake. Missing values and subjects not consuming the foods included in the simulation analyses were excluded. Based on the results of the studies conducted in humans so far, 8.6 g of phytosterols/-stanols per day was used as a cutoff for a safe level of intake. Results were considered to be significant at Po0.05. All statistical analyses were performed using SAS statistical software for windows, version 8.2 (SAS Institute Inc., Cary, NC, USA).
Results
In Table 2 , the distribution characteristics of phytosterol/-stanol intake for the 11 different simulation scenarios are presented for the whole population. There is a wide variation in simulated intake depending on which foods are being substituted. The cold cuts, sausages and salad dressing do not contribute much to the simulated intake. Below the simulation outcomes will be described for scenario 1A (enriched margarine) and scenario 3C (enriched margarine, cheese and yoghurt) separately. We deliberately chose to describe these scenarios in detail because the first (1A) has been the status quo in the Netherlands and in many other European countries for quite a few years, and the second (3C) was regarded as a 'realistic' scenario based on the current enrichment applications from the industry and the traditional Dutch food patterns. Also, the substitution of multiple products through this scenario resulted in the upper 10% of the population reaching our cutoff level of 8.6 g/day.
Scenario 1A: substitution of habitual margarine with sterol/stanol enriched margarine Predicting factors that explained most of the variance in the potential sterol/stanol intake in men who would substitute their margarine (Table 3) appeared to be SES, BMI, cholesterol level, the report of a stroke or myocardial infarction (MI) (Po0.05), and to a lesser extent age (P¼0.05). For women (Table 4) , age, SES, BMI, smoking, alcohol use and pregnancy appeared to be important factors that explained part of the variance in the potential sterol/stanol intake (Po0.05). The median consumption for men would be around 3 g/day, for women around 2 g/day. The 90th percentile of potential consumption levels for men and women did not reach our 'cutoff' level of 8.6 g/day. The direction and size of the effects of the explanatory factors is more clearly presented in Table 7 following the results of the multivariate regression analyses. For diet 1A (total explained variance for men was 2%, for women 1%), men and women in the lower SES categories have the potential to consume more sterols/stanols from enriched margarine than people in the highest SES category. People who reported a bad subjective health may consume less sterol/stanols through the enriched margarine than people with a good subjective health. The higher the BMI, the lower the potential sterol/stanol intake. For alcohol, results were different for men and women. Men who consume alcohol may have a higher intake than men who never drink, whereas women who never drink may have a higher intake compared to women who do drink. In women, Simulated intake of phytosterols/-stanols N De Jong et al especially the current smokers may have a higher intake compared to the never or exsmokers. Smoking in men did not contribute significantly to the explained variance of the regression model. In men, a tendency was shown with respect to measured cholesterol levels and the report of a stroke or MI: men who suffer from a high cholesterol level or a cholesterol-related disease may consume less than those who do not suffer. Pregnancy plays a role in women: pregnant women may potentially consume more sterol/stanols through phytosterol/-stanol-enriched margarines compared to the nonpregnant.
Scenario 3C: substitution of the habitual margarine, yoghurt and cheese with sterol/stanol-enriched margarine, yoghurt and cheese When three products (diet 3C) were substituted age, SES, BMI, smoking behaviour, alcohol consumption, cholesterol level and blood pressure significantly explained part of the variance in the simulated sterol/stanol intake in men (Table 5 ). For women (Table 6) , age, SES, subjective health, BMI, smoking, alcohol use and pregnancy were responsible factors for part of the variance in the simulated sterol/stanol intake from diet 3C. The median intake in men was between Simulated intake of phytosterols/-stanols N De Jong et al 5 and 6 g/day, in women between 4 and 5 g/day. In men, intake above the 90th percentile was between 9 and 10 g/ day: a level beyond our cutoff level of 8.6 g/day. The women in the upper part of the distribution did not quite reach this level with three products substituted, although the P90 for 115 pregnant women was 8.6 g/day. In all, 10% of the women did reach the cutoff level when four or more products were substituted (data not shown).
Results from the multivariate regression analyses (Table 7 , total explained variance for men was 2%, for women 3%) show that with increasing age, sterol/stanol intake also increased. This was significant for women, but not for men. For both men and women, a bad or moderate subjective health was associated with a lower simulated intake compared to the intake of persons reporting a good subjective health. Also for women, a low SES meant a lower Simulated intake of phytosterols/-stanols N De Jong et al simulated intake compared to the intake in the other SES categories. Moderate alcohol drinkers appear to consume more than the nondrinkers, but women who drank more than two glasses/day had in turn a lower simulated consumption than the nondrinkers. Current female and male smokers may consume less than the never smokers, whereas the exsmokers may consume more than the never smokers (statistically significant in women). Again, the higher the BMI, the less intake was simulated. As was observed in diet 1A, men who suffered from a high cholesterol level or a cholesterol-related disease (stroke or MI) consumed less than those who did not suffer. Those women who were pregnant appeared to consume more sterols/stanols through this diet.
Discussion
In case men completely replace three commonly consumed products (margarine, yoghurt and cheese) in their habitual diet with three identical but phytosterol/-stanol-enriched products their median intake exceeds the recommendation (maximal 3 g/day) and the highest 10% of intake in the male population exceeds a level beyond which no clinical effects Simulated intake of phytosterols/-stanols N De Jong et al have been studied properly (ie 8.6 g phytosterols/-stanols per day). Median intake in women exceeds the recommendation too. Women having an intake in the upper 10% of the distribution approach 8.6 g/day when substituting three products and exceed this level when substituting four products. Especially, age, BMI, SES, subjective health, smoking behaviour and alcohol consumption contributed to the variance in the simulated phytosterol/-stanol intake, although total variance explained was low. For women, an existing pregnancy increased the simulated intake results, whereas for men the existence of a high cholesterol level and/or the experience of events like stroke or MI decreased the simulated intake results. With increasing age, the simulated sterol/stanol intake increased too. This is somewhat difficult to explain as one would expect the younger potential users to consume most Simulated intake of phytosterols/-stanols N De Jong et al in absolute terms. From additional analyses in which age was included in the model as 10-year classes (data not shown), it appeared that especially the youngest age-category (20-29 y) had significantly lower intakes compared to the oldest agecategory (60-65 y), whereas the middle age-categories differed nonsignificantly from the oldest. Perhaps the types of food studied here are more popular foods among the older age-groups compared to the youngest age-group. This tendency (not statistically tested) also appeared for women, but not for men in the Dutch Nutrition Surveillance Reports (Hulshof et al, 1998) . With respect to BMI, it appeared that the higher the BMI, the lower the simulated intake. This might be explained by the fact that overweight people might be dieting and thus consume less, but it might also be explained by a consistent under-reporting of people in the highest BMI category. Indeed, the latter is supported by earlier findings in our data-sets that under-reporting for protein and energy intake increased with increasing BMI for both men and women independent of age, physical activity or level of education (Heerstrass et al, 1998) . In the lower SES categories, the simulated enriched margarine consumption appeared to be higher, whereas cheese and yoghurts, products that are part of diet 3C together with the margarine, may be more popular foods among the higher SES categories. Data from the Dutch National Food Consumption Survey showed indeed a higher consumption of visible fats and a lower consumption of cheese for people in a low SES group (Hulshof et al, 2003) . For diet 3C current smokers appear to consume less compared to the never smokers, which is also in agreement with general findings such as smokers having a decreased dietary intake and quitters having an increased intake and weight gain (Stamford et al, 1986; Hatsukami et al, 1993) . The intake of phytosterol/-stanol-enriched products in among others pregnant women is discouraged due to potential influence of the phytosterols/-stanols on gastrointestinal carotenoid uptake. The fact that in our simulation study pregnant women appeared to consume more of the margarine (diet 1A) and also more of the combination of margarine, cheese and yoghurt (diet 3C) compared to nonpregnant women, warrants the alertness and necessity of warning labels on packages. We furthermore see that a bad subjective health was associated with a lower consumption of the investigated foods. This result seem to contradict our earlier results that phytostanol-enriched margarine consumers were especially characterised by people with a bad subjective health (De Jong et al, 2003) . Yet, the results of the current study do not represent the actual number of people who take phytosterol/ -stanol-enriched margarines but only the simulated intake based on the consumption levels of ordinary foods among users of these foods. It could very well be that in the real situation more consumers with a bad subjective health consume the enriched margarines but only in smaller absolute amounts. Especially in men, high cholesterol levels and the experience of a stroke or MI influenced the consumption levels of either margarine, or the combination of margarine, yoghurt and cheese, whereas the prevalence of high cholesterol levels, and a stroke or MI event appear to be the same in both sexes. It would be of interest to investigate whether men are potentially regarded as a higher risk group for cardiovascular diseases compared to women by physicians and, as a consequence, receive dietary advice in an earlier phase. Several attempts to model the simultaneous use of multiple phytosterol/-stanol products have been made (Raulio et al, 2001; Scientific Committee on Food, 2002a; Scientific Committee on Food, 2003) . Our simulation results are of the same magnitude as observed by Raulio et al (2001) in Finland. The Fins conclude that if a consumer uses two to four enriched products, the daily intake of sterols/stanols can easily exceed 4 g and may even reach 9 g/day, especially among men. If the intake were calculated using the recommendations provided by the producers, instead of using the habitual amounts of intake of the common products, sterol/stanol intake would be higher in many cases. Yet, the researchers also state that these figures represent an estimate and only represent consumers who are faithful to use several enriched products. Often this is counterbalanced by the less enthusiastic users (Raulio et al, 2001) . The undertakings so far were restricted to only parts of the population (adolescents) (Scientific Committee on Food, 2003) or just the general population stratified for age and gender (Raulio et al, 2001; Scientific Committee on Food, 2002a) . In our study, we tried to simulate the intake figures of the general population with the help of more descriptive sociodemographic details in order to identify more specifically consumer risk groups. Our data are limited to the Dutch population. It is therefore that maximum intakes were revealed through combining bread spread use with dairy products use, as the Dutch population are often characterised by bread and dairy product eaters. This might not be the case in all European countries, and as EU regulations should be valid for all member states, it would be of interest to compare our results with other European data.
An important question is whether these general simulation results are useful. Indeed, our predictions are hypothetical, representing a worst-case scenario and are likely to be biased to the upper end when compared to the first rough data about the actual consumption on household level that appear to be lower than anticipated (Scientific Committee on Food, 2002c). Probably, only a selective (wealthy) group of enthusiastic people may consume multiple enriched products in large quantities. Conversely, we are of the opinion that it is of policy-making interest to present these type of figures, as the current daily practice for individuals is still hardly known, prone to alterations and difficult to measure. In the safety assessment procedures, performed by the EU Scientific Committee on Food, there is a fixed paragraph about anticipated intakes based on mean levels of consumption, but also based on high levels of consumption (sometimes defined as mean þ 2 Â standard deviation, sometimes defined otherwise through percentile values). To our understanding, the purpose of describing this wide distribution of potential intake figures is to be able to interpret the potential prevalence of risk of overconsumption and to be able to define potential future strategies to minimise the likelihood of overconsumption. At this moment, the number of applications of launching phytosterol-enriched foods on the market is rapidly increasing, so data on potential overconsumption will be needed. It is also therefore that the European Commission is urged to initiate monitoring programmes on the assessment of true total intakes in the population. Up till now, these programmes have not come into force, and hypothetical models are the only means available.
On the basis of the available data, the EU Scientific Committee on Food concluded that there is still no evidence of additional benefits at higher intakes than 1-3 g of sterols/ stanols per day, but that there is a possibility of high intakes inducing undesirable effects. Therefore, the Committee thinks it is still prudent to avoid any intakes higher than the above-mentioned range of 1-3 g/day (Scientific Committee on Food, 2003) . We wanted to have data available in the public domain that gives insight in the potential distribution of the population intake of the proposed products and to stress the importance of alertness towards the possibility of overconsumption in the worst case especially with respect to certain potential risk groups in the society. These data may help to clear the discussion about safety assessment. The development and market introduction of functional foods enriched with phytosterols is hampered and/or delayed by lack of data. For safety reasons, the Committee (Scientific Committee on Food, 2002a Food, , 2003 remains quite conservative by stating that 3 g phytosterols/day is the maximum safe intake. Perhaps our study can contribute to a standardised protocol to determine the distribution and variance in intake of the population and (risk)groups within the population in addition to (a) postlaunch monitoring studies investigating true intakes, and (b) scenario refinement to better approach the true situation.
When we compare our simulation results with actual data from a first EU postlaunch monitoring study presented by Unilever (Scientific Committee on Food, 2002c) after the launch of their product Becel pro.activ s , we learn that the real intake appears to be much lower than anticipated. The majority (75-95%) of the users were over 45 y old with a median margarine intake per household (not per person) between 3 g/day (France) and 12 g/day (the Netherlands and Germany). For more regular users, median intakes oberved per household were between 15 and 18 g/day. For all regular users, the upper intake (95th percentile) of margarine was between 27 g/day (France) and 45 g/day (the Netherlands). With a dose of 8 g phytosterols/100 g of margarine the figure of 45 g/day results in a phytosterol/-stanol intake of 3.6 g/day in the upper 95th percentile of the regular users. In most cases, the intake estimates for one-person households were similar to those of larger households, which indicated that predominantly one person per household was using the product. Apart from the fact that in 79-91% of the households, there were no children, no other sociodemographic data were presented. The presented household figures are quite low. The remark that was made within this context was that people may have been using phytostanol-enriched margarines (Benecol s ) too. The intake of these margarines was not measured, but simultaneous intake of these similar products should be investigated in the future (Scientific Committee on Food, 2002c ). Yet, these postlaunch figures even impose the question whether effectiveness might be reached by multiple enrichment of a wider variety of foods.
In the present simulation study, we assume that the determinants of consumption levels of the products under study (in this case, phytosterol/-stanol-enriched foods) are the same as the conventional products. Partly, this assumption will be valid (eg men tend to eat more bread than women and as a consequence may also use more bread spread whatever the brand). The assumption may not hold if specific characteristics of the enriched foods will cause other levels of use among specific subgroups. Cardiovascular health-and SES-related determinants may therefore be differently related to actual sterol/stanol intake due to the specific target group and high price of the enriched products. As well, a conflict of interest may occur in people having a high cholesterol level and/or having cardiovascular problems. On the one hand, they are advised to lower their fat intake to meet the dietary recommendations established for patients having cholesterol and/or cardiovascular problems. On the other hand, these people may learn that the intake of phytosterol-enriched margarine, and in the future perhaps also other fat-rich products such as cheese and sausages enriched with phytosterols are good for them in order to decrease their cholesterol level. Becaue of the high price tag of the phytosterol/-stanol-enriched products, overconsumption might not be so much of a problem yet. Conversely, there are people who may tend to take a little bit more of something that is good for you. In addition, the phytosterol/ -stanol-enriched products may be currently highly priced, but it may be expected that within an expanding market the prices will go down. So, it may be expected that in the near future the consumption of these products will grow and that the worst-case scenario may turn into a more realistic one.
Another problem in simulation studies like this is the dependence on the type of questionnaire used. Our analyses were based on results obtained with an FFQ that suitably measures usual consumption. The reproducibility and relative validity of this questionnaire has been described extensively and may be called satisfactory for some food groups but not for others. The Spearman rank correlation coefficients between estimates based on the FFQ and 12 24-recalls for the foods investigated in the current study varied between 0.38 (for cheese intake in females) to 0.79 (for milk and milk products intake in females). The intake of added fats and milk and milk products were overestimated in the FFQ. Comparison of mean intakes obtained with the FFQ with the Dutch National Food Consumption Survey which is based on 2-day diet records revealed for women 5-10% lower means of most of the food groups (Ocké et al, 1997a) . Although FFQ results, in general, are suitable for ranking groups with low, moderate, and high intakes of foods, the relative poor validity for some food groups should be kept in mind when evaluating the simulation results. A 5-10% overestimation of intake also reduces the number of people in the P90 of the population distribution with a similar magnitude.
In conclusion, our study is a first rough step that may help to identify and quantify consumer risk groups. This information may be a helpful tool for policy decision-makers to base their safety assessments on, to get a feeling for future potential risk groups, to have warrant of alertness programmes into action in case simulation results point to this, and to prioritise postlaunch activities. Worst-case scenario's are highly hypothetical, and based on very simple models with a lot of assumptions, but allow us to get the first insight in the intake distribution figures of a population in the case that no other (actual) data are available. Information about type of consumers and absolute consumption levels in the real setting after product launch remain absolutely necessary, in addition to scenario refinement to better estimate the acutal intake as well as human safety studies focusing on anticipated high levels of intake.
